193 related articles for article (PubMed ID: 36750998)
21. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
22. A systematic overview of chemotherapy effects in gastric cancer.
Janunger KG; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):309-26. PubMed ID: 11441938
[TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials.
Xiong B; Ma L; Cheng Y; Zhang C
Eur J Surg Oncol; 2014 Oct; 40(10):1321-30. PubMed ID: 25239442
[TBL] [Abstract][Full Text] [Related]
24. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer.
Xiong BH; Cheng Y; Ma L; Zhang CQ
Cancer Invest; 2014 Jul; 32(6):272-84. PubMed ID: 24800782
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of continuous intra-arterial infusion neoadjuvant chemotherapy with surgery for locally advanced gastric cancer: a preliminary pilot study.
Li B; Tang R; Zhang G; Cheng J; Chao M; Ding K
J Gastrointest Oncol; 2022 Jun; 13(3):968-976. PubMed ID: 35837182
[TBL] [Abstract][Full Text] [Related]
26. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
[TBL] [Abstract][Full Text] [Related]
27. Indications for neoadjuvant treatment based on risk factors for poor prognosis before and after neoadjuvant chemotherapy alone in patients with locally advanced rectal cancer.
Ogura A; Uehara K; Aiba T; Sando M; Tanaka A; Ohara N; Murata Y; Sato Y; Hattori N; Nakayama G; Ebata T; Kodera Y; Nagino M
Eur J Surg Oncol; 2021 May; 47(5):1005-1011. PubMed ID: 33189492
[TBL] [Abstract][Full Text] [Related]
28. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study.
Kubota Y; Hatakeyama S; Tanaka T; Fujita N; Iwamura H; Mikami J; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ito H; Yoshikawa K; Sasaki A; Kawaguchi T; Ohyama C
Oncotarget; 2017 Nov; 8(60):101500-101508. PubMed ID: 29254181
[TBL] [Abstract][Full Text] [Related]
29. Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal.
Gervaso L; Pellicori S; Cella CA; Bagnardi V; Lordick F; Fazio N
Ther Adv Med Oncol; 2021; 13():17588359211029559. PubMed ID: 34484429
[TBL] [Abstract][Full Text] [Related]
30. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.
Zhang X; Liu B; Wang R; Li X; Zhou W
Clin Transl Oncol; 2024 Mar; ():. PubMed ID: 38504071
[TBL] [Abstract][Full Text] [Related]
31. [Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer].
Chen J; Ye Q; Huang F
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):196-200. PubMed ID: 30799543
[TBL] [Abstract][Full Text] [Related]
32. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective.
Marino E; Graziosi L; Donini A
In Vivo; 2021; 35(6):3459-3466. PubMed ID: 34697182
[TBL] [Abstract][Full Text] [Related]
34. Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer.
Xu W; Fan Z; Wang L; He C; Ni Z; Hua Z; Zhu Z; Yang Z; Zheng Y; Feng R; Yan C; Li C; Yao X; Chen M; Yan M; Zhu Z; Liu W
Am J Transl Res; 2021; 13(3):1568-1579. PubMed ID: 33841680
[TBL] [Abstract][Full Text] [Related]
35. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial.
Oshima T; Yoshikawa T; Miyagi Y; Morita S; Yamamoto M; Tanabe K; Nishikawa K; Ito Y; Matsui T; Kimura Y; Yokose T; Hiroshima Y; Aoyama T; Hayashi T; Ogata T; Cho H; Rino Y; Masuda M; Tsuburaya A; Sakamoto J
Oncotarget; 2020 Jul; 11(30):2906-2918. PubMed ID: 32774771
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
37. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
38. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
[TBL] [Abstract][Full Text] [Related]
39. XPA expression is a predictive marker of the effectiveness of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
Wada T; Fukuda T; Shimomura M; Inoue Y; Kawanishi M; Tasaka R; Yasui T; Ikeda K; Sumi T
Oncol Lett; 2018 Mar; 15(3):3766-3771. PubMed ID: 29556276
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy-induced severe neutropenia is associated with histopathological response and survival in locally advanced gastric cancer.
Wu C; Wang T; Zhou H; Zhang X; Guo C; Chen Y; Zhao D
Transl Cancer Res; 2020 Jan; 9(1):280-293. PubMed ID: 35117182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
